Basecare (2170.HK) will be listed on the main board of HKEX on 8 February 2021. The total offering size assuming over-allotment option not exercised and fully exercised were US$235mm and US$271mm, respectively.
DISCLOSEABLE AND CONNECTED TRANSACTION DISPOSAL OF 35% EQUITY INTEREST IN CELLPRO BIOTECH
(1) 2021 REPORT OF THE BOARD OF DIRECTORS (2) 2021 REPORT OF THE BOARD OF SUPERVISORS (3) 2021 ANNUAL REPORT AND ITS ABSTRACT (4) 2021 FINANCIAL ACCOUNTS REPORT (5) 2022 FINANCIAL BUDGET (6) 2021 PROFIT DISTRIBUTION PLAN (7) RE-APPOINTMENT OF AUDITORS (8)
PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR; PROPOSED CHANGE IN USE OF PROCEEDS; PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION AND NOTICE OF 2022 FIRST EXTRAORDINARY GENERAL MEETING
PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION RESIGNATION OF EXECUTIVE DIRECTOR PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR AND PROPOSED CHANGE IN USE OF PROCEEDS
CHANGE IN INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE, THE NOMINATION COMMITTEE AND THE REMUNERATION AND APPRAISAL COMMITTEE
RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR, PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CLOSURE OF REGISTER OF MEMBERS OF H SHARES
(1) 2020 REPORT OF THE BOARD OF DIRECTORS (2) 2020 REPORT OF THE BOARD OF SUPERVISORS (3) 2020 ANNUAL REPORT AND ITS ABSTRACT (4) 2020 FINANCIAL ACCOUNTS REPORT (5) 2021 FINANCIAL BUDGET (6) 2020 PROFIT DISTRIBUTION PLAN (7) RE-APPOINTMENT OF AUDITORS (8)